Sun Pharma Advanced Research jumps 11%, extends 2-day rally as US court clears Sezaby PRV
[hfe_template id='11223']
[ad_1]
Shares of Sun Pharma Advanced Research Company (SPARC) surged 11% to Rs 179.5 on the BSE on Wednesday, marking a second consecutive day of gains following a 20% jump in the previous session. The rally comes after a favourable ruling by a U.S. court concerning the Priority Review Voucher (PRV) for SPARC’s drug Sezaby. On December 2, 2025, SPARC announced that the U.S. District Court for the District of Columbia granted its motion for summary judgment in the case concerning the issuance of a PRV linked to Sezaby’s approval. The court ruled that the U.S. Food and Drug Administration’s (FDA) decision to withhold the PRV was “contrary to law,” noting that no drug product containing phenobarbital sodium had been “previously approved,” as defined under the relevant statute. The court has provided a 60-day window for an appeal. Commenting on the decision, SPARC CEO Anil Raghavan said, “We are pleased with the ruling issued today by the U.S. Distr...